{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:11:52Z","timestamp":1793045512151,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s12072-025-10783-w","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T06:39:07Z","timestamp":1740724747000},"page":"1172-1186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Analysis of risk factors for immune checkpoint inhibitor-associated liver injury: a retrospective analysis based on clinical study and real-world data"],"prefix":"10.1007","volume":"19","author":[{"given":"Bitao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jierong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"6","key":"10783_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.cllc.2024.05.002","volume":"25","author":"V Velcheti","year":"2024","unstructured":"Velcheti V, Rai P, Kao YH, et al. 5-year real-world outcomes with frontline pembrolizumab monotherapy in PD-L1 expression \u2265 50% advanced NSCLC [J]. Clin Lung Cancer. 2024;25(6):502-508.e3","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10783_CR2","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","volume":"183","author":"MF Krummel","year":"1996","unstructured":"Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells[J]. J Exp Med. 1996;183(6):2533\u20132540","journal-title":"J Exp Med"},{"issue":"18","key":"10783_CR3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway [J]. N Engl J Med. 2016;375(18):1767\u20131778","journal-title":"N Engl J Med"},{"issue":"3","key":"10783_CR4","doi-asserted-by":"publisher","first-page":"e0063","DOI":"10.1097\/HC9.0000000000000063","volume":"7","author":"C Zheng","year":"2023","unstructured":"Zheng C, Huang S, Lin M, et al. Hepatotoxicity of immune checkpoint inhibitors: what is currently known [J]. Hepatol Commun. 2023;7(3):e0063","journal-title":"Hepatol Commun"},{"issue":"32","key":"10783_CR5","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","volume":"27","author":"D Remash","year":"2021","unstructured":"Remash D, Prince DS, McKenzie C, et al. Immune checkpoint inhibitor-related hepatotoxicity: a review [J]. World J Gastroenterol. 2021;27(32):5376\u20135391","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10783_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis [J]. JAMA Oncol. 2018;4(12):1721\u20131728","journal-title":"JAMA Oncol"},{"key":"10783_CR7","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1007\/s00432-022-04340-3","volume":"149","author":"A Miah","year":"2022","unstructured":"Miah A, Tinoco G, Zhao S, et al. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival [J]. J Cancer Res Clin Oncol. 2022;149:2235\u20132242","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10783_CR8","first-page":"490","volume":"41","author":"K Yin","year":"2022","unstructured":"Yin K. Influence factors and prediction model of immune-mediated hepatotoxicity in patients with malignant melanoma treated with pembrolizumab [J]. Chin J New Drugs Clin Rem. 2022;41(8):490\u2013494","journal-title":"Chin J New Drugs Clin Rem."},{"key":"10783_CR9","doi-asserted-by":"crossref","unstructured":"Jing Y, Zhang Y, Wang J, et al. (2021) Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy [J]. JNCI. 113(10): 1396\u20131404.","DOI":"10.1093\/jnci\/djab035"},{"issue":"1","key":"10783_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12882-023-03171-9","volume":"24","author":"P Chen","year":"2023","unstructured":"Chen P, Zhu J, Xu Y, et al. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database [J]. BMC Nephrol. 2023;24(1):107","journal-title":"BMC Nephrol"},{"key":"10783_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews [J]. Int J Surg. 2021;88: 105906","journal-title":"Int J Surg"},{"issue":"4","key":"10783_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors[J]. Ann Intern Med. 2013;158(4):280\u2013286","journal-title":"Ann Intern Med"},{"issue":"6","key":"10783_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u2013436","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10783_CR14","doi-asserted-by":"publisher","first-page":"e000871","DOI":"10.1136\/jitc-2020-000871","volume":"8","author":"A Samani","year":"2020","unstructured":"Samani A, Zhang S, Spiers L, Suwaidan AA, Merrick S, Tippu Z, et al. Impact of age on the toxicity of immune checkpoint inhibition. J Immunother Cancer. 2020;8(2):e000871","journal-title":"J Immunother Cancer."},{"key":"10783_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","volume":"129","author":"C Baldini","year":"2020","unstructured":"Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, et al. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. Eur J Cancer. 2020;129:71\u201379","journal-title":"Eur J Cancer"},{"key":"10783_CR16","doi-asserted-by":"publisher","first-page":"619385","DOI":"10.3389\/fonc.2021.619385","volume":"11","author":"X Huang","year":"2021","unstructured":"Huang X, Tian T, Zhang Y, Zhou S, Hu P, Zhang J. Age-associated changes in adverse events arising from anti-PD-(L)1 therapy. Front Oncol. 2021;11:619385","journal-title":"Front Oncol"},{"key":"10783_CR17","doi-asserted-by":"publisher","first-page":"786046","DOI":"10.3389\/fimmu.2021.786046","volume":"12","author":"SK Wong","year":"2021","unstructured":"Wong SK, Nebhan CA, Johnson DB. Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy. Front Immunol. 2021;12:786046","journal-title":"Front Immunol"},{"issue":"8","key":"10783_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1634\/theoncologist.2016-0450","volume":"22","author":"AS Betof","year":"2017","unstructured":"Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist. 2017;22(8):963\u2013971","journal-title":"Oncologist"},{"issue":"1","key":"10783_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-\u017dugich","year":"2018","unstructured":"Nikolich-\u017dugich J. The twilight of immunity: emerging concepts in aging of the immune system [J]. Nat Immunol. 2018;19(1):10\u201319","journal-title":"Nat Immunol"},{"issue":"11","key":"10783_CR20","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/ijms20112810","volume":"20","author":"WX Huff","year":"2019","unstructured":"Huff WX, Kwon JH, Henriquez M, et al. The evolving role of CD8+ CD28\u2212 immunosenescent T cells in cancer immunology[J]. Int J Mol Sci. 2019;20(11):2810","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10783_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","volume":"16","author":"S Valpione","year":"2018","unstructured":"Valpione S, Pasquali S, Campana LG, Piccin L, Mocellin S, Pigozzo J, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med. 2018;16(1):94","journal-title":"J Transl Med"},{"issue":"2","key":"10783_CR22","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","volume":"50","author":"M Delaunay","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2):1700050","journal-title":"Eur Respir J."},{"issue":"8","key":"10783_CR23","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.autrev.2020.102590","volume":"19","author":"P Triggianese","year":"2020","unstructured":"Triggianese P, Novelli L, Galdiero MR, Chimenti MS, Conigliaro P, Perricone R, et al. Immune checkpoint inhibitors-induced autoimmunity: the impact of gender. Autoimmun Rev. 2020;19(8):102590","journal-title":"Autoimmun Rev"},{"key":"10783_CR24","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3389\/fimmu.2018.02279","volume":"9","author":"VR Moulton","year":"2018","unstructured":"Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol. 2018;9:2279","journal-title":"Front Immunol"},{"key":"10783_CR25","doi-asserted-by":"publisher","first-page":"1326078","DOI":"10.3389\/fimmu.2023.1326078","volume":"14","author":"L Kocheise","year":"2024","unstructured":"Kocheise L, Piseddu I, Vonderlin J, et al. PD-1\/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease [J]. Front Immunol. 2024;14:1326078","journal-title":"Front Immunol"},{"issue":"1","key":"10783_CR26","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.1038\/s41598-021-88307-3","volume":"11","author":"D Michailidou","year":"2021","unstructured":"Michailidou D, Khaki AR, Morelli MP, et al. Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Sci Rep. 2021;11(1):9029","journal-title":"Sci Rep"},{"key":"10783_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21\u201329","journal-title":"Eur J Cancer"},{"issue":"1","key":"10783_CR28","doi-asserted-by":"publisher","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","volume":"8","author":"J Haanen","year":"2020","unstructured":"Haanen J, Ernstoff M, Wang Y, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer. 2020;8(1):e000604","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10783_CR29","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14740338.2022.2134854","volume":"21","author":"J Pan","year":"2022","unstructured":"Pan J, et al. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Exp Opin Drug Safe. 2022;21(10):1275\u20131287","journal-title":"Exp Opin Drug Safe"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10783-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-025-10783-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10783-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T18:48:42Z","timestamp":1759949322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-025-10783-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10783"],"URL":"https:\/\/doi.org\/10.1007\/s12072-025-10783-w","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bitao Wang, Shaowei Zhuang, Shengnan Lin, Jierong Lin, Wanxian Zeng, Bin Du, Jing Yang declare that te research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}